Analyst Estimates

Analytical Approach on: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) soared 2.04% during previous trade, a total of 1.64M shares exchanged hands compared with its average trading volume of 1.73M shares whereas its relative volume is 0.75. The stock has a market capitalization of $20.22B along with 211.19M outstanding shares. Stock’s intraday price range hit the peak level of $97.10 and touched the lowest level of $95.37.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 3/31/17 and according to 19 analysts stock’s price will reach at $116.11 during 52 weeks with standard deviation of 10.85. Stock’s minimum price target estimates has been figured out at $80 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 45% from its latest closing price of $96.69.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 3/23/17 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $100 over the next one year. Stock’s 52-week target was retained at $118.13, the estimates indicates a standard deviation of 10.85.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.59. ABR value is precisely based on brokerage recommendations, where out of 16 brokerage recommendations 10 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 2/2/17 the stock of Edwards Lifesciences Corp (NYSE:EW) downgraded by Leerink Partners from Outperform to Mkt Perform. However previously on 1/3/17 it was upgraded by Guggenheim from Neutral to Buy. A research note issued on 11/8/16 the stock was upgraded by Northland Capital from Market Perform to Outperform.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year plunged -8.85% whereas its year to date (YTD) performance indicated a bullish trend of 3.19%. During the last six months the stock slipped -16.32%. Quarterly performance of the company shows optimistic momentum of 0.94% while its last one month trend is positive with 2.77%. Stock’s weekly performance expressed up trend of 3.30%.

The company’s price sits 4.01% above from its 50-day moving average of $93.61 and -4.33% below from the stock’s 200-day moving average which is $95.46. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -20.58% away from the 52-week high price of $121.75 and +19.19% far from the 52-week low price of $81.12.

According to consensus agreement of 20 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.82 in their quarterly report and it is expected to announce the company’s results on 4/25/17 After Market Close. For the current quarter the company has high EPS estimates of $0.86 in contradiction of low EPS estimates of $0.79. However a year ago for the same quarter the company has reported $0.71 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $3.41 according to the sentiments of 21 analysts, while its lowest earnings estimates are $3.32 and highest earnings estimates are $3.6.

According to 18 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $777.83M meanwhile the company has high revenue estimates of $793M in contradiction of low revenue estimates of $760M. For the current year the company’s revenue estimates are $3.26B compared to low analyst estimates of $3.13B and high estimates of $3.38B according to the projection of 21 analysts.

Previous ArticleNext Article
0 Shares
Share
Tweet
Share
Pin
Stumble
+1